Spectrum Pharmaceuticals, Inc. (SPPI) News
Filter SPPI News Items
SPPI News Results
|Loading, please wait...|
SPPI News Highlights
- For SPPI, its 30 day story count is now at 4.
- Over the past 22 days, the trend for SPPI's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about SPPI are DRUG.
Latest SPPI News From Around the Web
Below are the latest news stories about Spectrum Pharmaceuticals Inc that investors may wish to consider to help them evaluate SPPI as an investment opportunity.
The shares of Spectrum Pharmaceuticals (NASDAQ:SPPI) are trading marginally lower in the pre-market on Wednesday after the commercial-stage biotech company announced the resignation of its Chief Financial Officer Kurt Gustafson. According to a regulatory filing, Mr. Gustafson has notified the company of his decision on Feb. 23, indicating his resignation...
B.Riley Financial analyst Mayank Mamtani maintained a Buy rating on Spectrum Pharmaceuticals (SPPI – Research Report) today and set a price target of $6.00. The company's shares closed last Friday at $0.72, close to its 52-week low of $0.60. According to TipRanks.com, Mamtani 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -18.7% and a 29.8% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Madrigal Pharmaceuticals, and Cognition Therapeutics. Currently, the analyst consensus on Spectrum Pharmaceuticals is a Strong Buy with an average price target of $6.67.
HENDERSON, Nev., February 11, 2022--Spectrum Pharmaceuticals Announces Acceptance of New Drug Application Filing for Poziotinib
The heavy selling pressure might have exhausted for Spectrum Pharma (SPPI) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Good morning, investor!
Check out these penny stocks insiders are buying Losers ION Geophysical Corporation (NYSE: IO ) shares fell 53.6% to settle at $0.51 on Thursday. Epizyme, Inc. (NASDAQ: EPZM ) shares dipped 44.2% to close at $1.06 on Thursday after the company priced an underwritten public offering of 56,666,667 shares at $1.50 per share, before underwriting discounts. TG Therapeutics, Inc. (NASDAQ: TGTX ) dropped 40.5% to settle at $8.27 on Thursday. TG Therapeutics said the FDA imposed partial clinical hold on select studies of U2 and its components for CLL and NHL. Cyngn Inc. (NASDAQ: CYN ) tumbled 35.7% to close at $1.62. PetVivo Holdings, Inc. (NASDAQ: PETV ) fell 35% to close at $1.30. PetVivo recently announced distribution of its veterinary medical device, SPRYNG, by Vetcove, Inc. Advanced Human...
Gap Inc. is leaving the S&P 500 index , index provider S&P Dow Jones Indices said late Wednesday, underscoring the challenges faced by retailers in recent years. Constellation Energy Corp. will replace Gap in the key equity index, with the retailer replacing fast-food chain Jack in the Box Inc. in the S&P MidCap 400. Jack in the Box will replace Spectrum Pharmaceuticals Inc. in the S&P SmallCap 600, S&P Dow Jones said. The changes take effect on Feb. 3. Exelon Corp. is spinning off Constellation Energy in a transaction expected to close Feb. 2. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600:
HENDERSON, Nev., January 20, 2022--Spectrum Pharmaceuticals to Participate in B. Riley Securities 2022 Virtual Oncology Conference
Thinking about buying stock in China SXT Pharmaceuticals, Virgin Galactic, Citigroup, Novavax, or Spectrum Pharmaceuticals?
NEW YORK , Jan. 14, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SXTC, SPCE, C, NVAX, and SPPI. Full story available on Benzinga.com